Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s focused strategy for long-term sustainable growth, ...

Edwards Lifesciences (NYSE:EW) today announced one-year data highlighting strong performance from its Sapien 3 Ultra Resilia ...

Edwards' SAPIEN 3 Ultra RESILIA Valve continues to deliver excellent outcomes for patients in real-world data.

Introduction: Migration of a transcatheter aortic valve replacement (TAVR) is a rare, life-threatening complication that typically ... Following the development of severe bioprosthetic regurgitation, ...

Abbott has taken a step forward in the development of a new addition to its structural heart portfolio, completing the first ...

He has also acted as a Consultant for Sorin and received research support from Edwards Lifesciences. Jean G. Dumesnil received Speakers' Bureau honoraria from Medtronic and St Jude Medical.

NEW YORK, NY / ACCESSWIRE / December 3, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to ...

New York, New York-- (Newsfile Corp. - December 3, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE ...

Edwards Lifesciences Corp. revealed excellent one-year data highlighting the performance of its newest generation Sapien 3 Ultra Resilia valve. Patients treated with the transcatheter aortic valve ...